Controlling IOP in glaucoma patients, whether or not they have ocular hypertension, is important because large clinical trials involving tens of thousands of patients repeatedly demonstrate that significant, sustained IOP reduction slows or halts vision loss. Unfortunately, current daily medical treatments do not target the diseased conventional pathway and do not lower IOP sufficiently in most people with glaucoma. Therefore, finding new, more effective ways to medically control IOP by targeting the conventional pathway is a central goal the Stamer Laboratory.

 

Using molecular, cellular and organ-based model systems, my laboratory seeks to identify and validate novel drug targets in the human conventional outflow pathway such that novel treatment of ocular hypertension and glaucoma can be developed.